Exelixis
EXEL
#1696
Rank
$9.90 B
Marketcap
$34.69
Share price
-3.83%
Change (1 day)
48.63%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) Fails to deliver data

Key failure to deliver metrics for Exelixis:

A Failure to deliver also known as fails-to-deliver or FTD occurs when a buyer or seller is unable to meet his trading obligations. FTDs for US listed companies are reported to the SEC and published twice a month. Therefore there is a certain delay between the reporting and the publishing of the data.

Failures to deliver for Exelixis (EXEL) - 3 months history

Number of shares, 3 months chart

Biweekly Failures to deliver volume for Exelixis (EXEL) - since 2013

Volume in USD (price x number of shares), data since 2013

Exelixis (EXEL) Failure to deliver volume, Year over Year

Year Volume (Price x Shares) Change
2024$9.86 M52.17%
2023$6.48 M-41.81%
2022$11.14 M-31.9%
2021$16.36 M-20.71%
2020$20.64 M303.63%
2019$5.11 M-70.5%
2018$17.33 M8.82%
2017$15.92 M-17.35%
2016$19.27 M-75.68%
2015$79.23 M19.37%
2014$66.37 M258.49%
2013$18.51 M

FTD volume in the last 3 months for similar companies or competitors

Company FTD volume (3 months) FTD volume (1 year) Country
$57.35 M$99.79 M๐Ÿ‡ฌ๐Ÿ‡ง UK
$11.17 M$72.51 M๐Ÿ‡ซ๐Ÿ‡ท France
$24.78 M$98.35 M๐Ÿ‡บ๐Ÿ‡ธ USA
$43.55 M$0.32 B๐Ÿ‡บ๐Ÿ‡ธ USA
$62.92 M$0.25 B๐Ÿ‡บ๐Ÿ‡ธ USA
$81.31 M$0.33 B๐Ÿ‡บ๐Ÿ‡ธ USA
$48.65 M$0.35 B๐Ÿ‡บ๐Ÿ‡ธ USA
$0.26 M$1.26 M๐Ÿ‡บ๐Ÿ‡ธ USA
N/A$0.04 M๐Ÿ‡บ๐Ÿ‡ธ USA